Earnings ·
Sionna Therapeutics reported second quarter 2026 financial results on August 6, 2026
SIONSionna Therapeutics, Inc.
Sionna Therapeutics reported second quarter 2026 financial results on August 6, 2026. The company incurred a net loss of $29.9 million and spent $21.9 million on research and development, up from $15.4 million in the prior year period. General and administrative expenses rose to $10.6 million from $6.5 million. Cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026, which management expects will fund operations into 2028. Clinically, the PreciSION CF Phase 2a trial for SION-719 and a Phase 1 dual combination trial for SION-451 are on track to report topline data in summer 2026. Sionna Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cystic fibrosis.